Vitalyn Biotech Retatrutide 40mg Pen

Vitalyn Biotech Retatrutide is a next-generation triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors, producing more aggressive fat loss than single-agonist compounds like Semaglutide. In phase 2 clinical trials published in the New England Journal of Medicine (2023), participants receiving the highest dose of Retatrutide lost an average of 24.2% of their body weight over 48 weeks, making it the most effective weight-loss peptide ever trialled. This significantly exceeds the 14.9% achieved by Semaglutide and the 22.5% achieved by Tirzepatide in their respective trials.

How Retatrutide Works

Retatrutide’s triple mechanism distinguishes it from earlier GLP-1 drugs:

• GLP-1 receptor agonism: suppresses appetite, slows gastric emptying, and enhances insulin sensitivity. This is the same mechanism as Semaglutide (Ozempic/Wegovy)
• GIP receptor agonism: amplifies the GLP-1 effect on appetite suppression and improves glucose metabolism. This dual action (shared with Tirzepatide) produces greater weight loss than GLP-1 alone
• Glucagon receptor agonism: the unique third mechanism. Glucagon stimulates hepatic fat oxidation (the liver burns stored fat for energy) and increases resting energy expenditure. This component is what pushes Retatrutide’s fat loss beyond what Tirzepatide achieves

The glucagon component is particularly relevant for athletes and bodybuilders because it directly targets visceral and hepatic fat stores, the metabolically active fat deposits that are hardest to lose through diet and training alone. The increase in resting energy expenditure means more calories are burned at rest, compounding the caloric deficit from appetite suppression.

Dosage Protocol

Retatrutide requires gradual dose escalation to minimise gastrointestinal side effects:

• Week 1-4: 1mg once weekly (subcutaneous injection)
• Week 5-8: 2mg once weekly
• Week 9-12: 4mg once weekly
• Week 13+: 8-12mg once weekly (target maintenance dose)
• Administration: subcutaneous injection in the abdomen or thigh. Same day each week
• Injection timing: morning or evening. Consistency matters more than time of day

Retatrutide vs Semaglutide vs Tirzepatide

• Semaglutide (available here): single-agonist (GLP-1 only). Average weight loss 14.9% over 68 weeks. Well-established safety profile. Lower cost
• Tirzepatide: dual-agonist (GLP-1 + GIP). Average weight loss 22.5% over 72 weeks. Stronger than Semaglutide, well-tolerated
• Retatrutide (this product): triple-agonist (GLP-1 + GIP + glucagon). Average weight loss 24.2% over 48 weeks. The most aggressive option. Newer compound with less long-term safety data

Side Effects

• Nausea: most common, particularly during dose escalation. Resolves for most users after 2-4 weeks at each dose level
• Diarrhoea or constipation: gastrointestinal adjustment period. Usually temporary
• Reduced appetite: pronounced. Ensure adequate protein intake (minimum 2g/kg bodyweight) to prevent muscle loss during aggressive fat loss
• Mild increase in heart rate: 2-4 bpm average increase observed in trials. Monitor if you have cardiovascular concerns
• Injection site reactions: mild redness. Rotate injection sites

Key Facts

• Active ingredient: Retatrutide
• Manufacturer: Vitalyn Biotech
• Class: GLP-1/GIP/Glucagon triple receptor agonist
• Half-life: approximately 6 days (once-weekly dosing)
• Testosterone suppression: none
• PCT required: no
• Liver toxicity: none

Browse our full weight loss range. For steroid-based cutting compounds, read our Anavar Guide or Clenbuterol Guide.